SCHEMBL3579238

SCHEMBL3579238

O=S1(=O)N=NC(c2ccccc2)c2cc(Cl)ccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ATM Q13315 1/20 0.33
TRPM4 Q8TD43 1/20 0.32
TRPM5 Q9NZQ8 1/20 0.32
ALOX12 P18054 1/20 0.32
CACNB4 O00305 1/20 0.31
CACNA1A O00555 1/20 0.31
CACNA1G O43497 1/20 0.31
CACNG3 O60359 1/20 0.31
CACNA1F O60840 1/20 0.31
CACNA1H O95180 1/20 0.31
CACNB3 P54284 1/20 0.31
CACNA2D1 P54289 1/20 0.31
CACNG7 P62955 1/20 0.31
CACNA1B Q00975 1/20 0.31
CACNA1D Q01668 1/20 0.31
CACNB1 Q02641 1/20 0.31
CACNG1 Q06432 1/20 0.31
CACNB2 Q08289 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2791467 0.81 EDNRA (0.32) CA1CA2
SCHEMBL9565875 0.67 CYP19A1 (0.40) CA1CA2ATMTRPM4TRPM5
SCHEMBL7248919 0.67 CA1 (0.50) CA1CA2ATMTRPM4TRPM5
SCHEMBL2796293 0.66 ALDH1A1 (0.40) CA1CA2
SCHEMBL5621775 0.64 CA12 (0.32) CA1CA2
SCHEMBL2793795 0.60 PKM (0.34) CA1CA2
SCHEMBL11464561 0.60 CA12 (0.32) CA1CA2
SCHEMBL11519279 0.60 MEN1 (0.46) ATMCACNB4CACNA1ACACNA1GCACNG3
SCHEMBL12197253 0.59 ALOX12 (0.46) TRPM4TRPM5ALOX12CACNB4CACNA1A
SCHEMBL23088788 0.59 CYP19A1 (0.42) CA1CA2ATMTRPM4TRPM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) 2010-07-29 US disclosed
EP-2064197-A2 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) 2009-06-03 EP disclosed
WO-2008020256-A2 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYÓGYSZERGYÁR_Nyilvánosan Müködö Részvénytársaság (HU) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE TDO2, DHODH, DHPS CA1 2614/4885CA2 1607/4885ATM 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.